checkAd

     122  0 Kommentare BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020

    RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its third quarter 2020 financial results before the open of the U.S. financial markets on Thursday, November 5, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

    Conference Call Dial-In & Webcast Information:

    Date:  Thursday, November 5, 2020
    Time: 8:30 AM Eastern Time
    Domestic: 877-407-0789
    International: 201-689-8562
    Conference ID: 13710272
    Webcast: http://public.viavid.com/index.php?id=141502

    About BioDelivery Sciences International, Inc.
    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

    2020 BioDelivery Sciences International, Inc.  All rights reserved.

    Contact:
    Bob Yedid
    LifeSci Advisors
    646-597-6989
    Bob@LifeSciAdvisors.com





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020 RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) - BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced …